Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)
Close on Nov 17, 2026Market cap $122.22MP/E –Yield –
Fate Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Fate Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$133.59M. For fiscal 2025 it was -$147.70M. The highest annual figure on record is -$13.29M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$147.70M | – |
| FY2024 | Dec 31, 2024 | -$210.28M | – |
| FY2023 | Dec 31, 2023 | -$190.51M | – |
| FY2022 | Dec 31, 2022 | -$308.39M | – |
| FY2021 | Dec 31, 2021 | -$216.99M | – |
| FY2020 | Dec 31, 2020 | -$128.09M | – |
| FY2019 | Dec 31, 2019 | -$100.73M | – |
| FY2018 | Dec 31, 2018 | -$67.09M | – |
| FY2017 | Dec 31, 2017 | -$42.13M | – |
| FY2016 | Dec 31, 2016 | -$31.96M | – |
| FY2015 | Dec 31, 2015 | -$27.78M | – |
| FY2014 | Dec 31, 2014 | -$24.90M | – |
| FY2013 | Dec 31, 2013 | -$17.68M | – |
| FY2012 | Dec 31, 2012 | -$13.56M | – |
| FY2011 | Dec 31, 2011 | -$13.29M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.13M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.74M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.97M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$61.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$52.38M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$48.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$62.57M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$64.42M | – |
| Q3 FY2022 | Sep 30, 2022 | -$86.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$83.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$74.47M | – |
| Q4 FY2021 | Dec 31, 2021 | -$69.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$46.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$33.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$31.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$28.71M | – |
| Q1 FY2020 | Mar 31, 2020 | -$34.49M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.08M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.12M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.08M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.45M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.74M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.69M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.61M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.24M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.34M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.57M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.97M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.65M | – |
| Q3 FY2016 | Sep 30, 2016 | -$8.39M | – |
See a number that looks wrong?